CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer

Karabon, Lidia; Pawlak, Edyta; Tomkiewicz, Anna; Jedynak, Anna; Passowicz−Muszyńska, Ewa; Zajda, Katarzyna; Jonkisz, Anna; Jankowska, Renata; Krzakowski, Maciej; Frydecka, Irena

doi:10.1016/j.humimm.2011.05.010

Cited by 42 publications

(34 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For rs231775, 64 studies involved a total of 23617 cases and 27261 controls [10-15, 17-73]. Moreover, there were 30 studies with 9675 cases and 9623 controls for rs3087243 [12-15, 17, 23-25, 27-29, 31, 32, 35, 37, 40, 41, 44, 45, 47, 53, 54, 61, 63, 65, 66, 73-75]. Additionally, rs4553808 was in 17 studies [12, 14, 15, 23, 28, 29, 31, 37, 41, 44, 47, 49, 51, 52, 62, 73, 76], rs5742909 was in 32 studies [12, 14, 15, 20, 24, 25, 28-30, 32, 34, 35, 39-41, 45, 47, 52-54, 56, 57, 59, 62, 63, 65, 66, 70, 73, 76, 77], rs733618 was in 14 studies [13, 23, 28, 37, 44, 47, 51, 52, 62, 73-76, 78], and they were analysed.…”

Section: Resultsmentioning

confidence: 99%

Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies

Fang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: CTLA-4 polymorphisms are associated with susceptibility to various cancers, but the results are often conflicting. Hence, we performed a comprehensive meta-analysis to quantitatively investigate the association between CTLA-4 polymorphisms (rs231775, rs4553808，rs5742909, rs3087243 or rs733618) and cancer risk. Methods: Data were collected from PubMed and Web of Science. A total of 67 case-control studies were selected for quantitative analysis. Stata (Version 12) software was used to calculate the odds ratio (OR) and 95% confidence interval (CI) to evaluate the strength of the associations. Subgroup meta-analysis was conducted based on ethnicity and cancer type. Heterogeneity tests, sensitivity analysis, and publication bias assessments were also performed. Results: rs231775, rs4553808 and rs5742909 but not rs3087243 and rs733618 were significantly related to cancer risk. In analyses stratified by ethnicity, both rs231775 and rs4553808 were significant susceptibility polymorphisms in an Asian population but not in a Caucasian population. Moreover, there were stronger associations between the rs231775 polymorphism and increased risk of bone, breast, liver, head and neck and pancreatic cancers. Additionally, rs4553808 was associated with significantly increased susceptibility to breast cancer and head and neck cancer. Conclusion: rs231775, rs4553808 and rs5742909 may be used as predictive genetic biomarkers for cancer predisposition. Combined detection of CTLA-4 SNPs could be a useful tool for prediction of cancer susceptibility in clinical practice.

show abstract

Section: Resultsmentioning

confidence: 99%

Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies

Fang

Huang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…An increased frequency of ICOS + CD4 + T cells in blood samples can work as a pharmacodynamic biomarker, which promisingly can be used for making decisions regarding different doses, However, few studies have focused on the relationship between NSCLC treatment and ICOS expression. The polymorphisms in ICOS genes (ICOSc.1554+4GT{8_15} {>10}) were previously associated with susceptibility to disease and OS rates of NSCLC in a Polish population 50 but not as an independent risk factor. Therefore, this merits more studies to define the therapeutic ability for ICOS in NSCLC patients with anti-CTLA-4 therapy.…”

Section: Predictive Markers Of Anti-ctla-4 Therapymentioning

confidence: 99%

Highlights on immune checkpoint inhibitors in non–small cell lung cancer

Shen

Ren²

2017

Tumour Biol.

View full text Add to dashboard Cite

The treatment of advanced or refractory non-small cell lung cancer has been historically difficult owing to the lack of studies on effective systemic cure. The progress in lung cancer treatment has plateaued, necessitating new options for additional benefits. Immune checkpoint proteins are co-inhibitory factors that can diminish the antigen-specific immune responses by attenuating the regulatory role of cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, lymphocyte-activation gene 3, and T-cell immunoglobulin mucin-3. The therapeutic strategies targeting immune checkpoints mainly focus on the monoclonal antibody of these regulatory factors, which may facilitate clinical decision making. An enhanced understanding of the drug-resistance mechanisms and the therapeutic efficacy regulation will provide opportunities to improve the clinical outcomes of non-small cell lung cancer patients. Preclinical and clinical trials on these key immune-regulatory agents, which has heralded a new era in immuno-oncology in non-small cell lung cancer treatment, are currently in development. KeywordsNon-small cell lung cancer, immune checkpoint, cytotoxic T-lymphocyte-associated protein 4, programmed cell death-1, programmed cell death ligand-1, tumor immunotherapy Date

show abstract

“…Thus, it is extremely likely that CTLA-4 polymorphisms are involved in the pathogenesis of cervical cancer. The most frequently studied CTLA-4 polymorphisms are +49 A/G (rs231775), -318 C/T (rs5742909) and CT60 G/A (rs3087243) (6,(20)(21)(22). A number of studies have been previously performed to determine whether these polymorphisms confer susceptibility to cervical cancer in various populations Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: A meta-analysis (6,(23)(24)(25)(26)(27)(28)(29), however, results have been inconclusive.…”

Section: Introductionmentioning

confidence: 99%

Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: A meta-analysis

Qiu

Tang

Yin

et al. 2013

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) polymorphisms have been examined for associations with cervical cancer in various countries. The results, however, are inconclusive. The present study aimed to explore whether CTLA-4 +49 A/G, -318 C/T and CT60 G/A polymorphisms confer susceptibility to cervical cancer. A meta-analysis was performed with 7,794 subjects included in 15 case-control studies that were published up to January 1, 2013. The results from the meta-analysis indicated that there were no significant associations between the risk of cervical cancer and the three studied polymorphisms [+49 A/G: Odds ratio (OR), 0.94 and 95% confidence interval (CI), 0.82-1.07 for GG+AG vs. AA; -318 C/T: OR, 1.33 and 95% CI, 0.82-2.16 for TT+TC vs. CC; and CT60: OR, 0.98 and 95% CI, 0.72-1.33 for AA+AG vs. GG]. Stratified analyses by ethnicity for the +49 A/G and -318 C/T polymorphisms suggested that Asian populations had a decreased risk of cervical cancer for the +49 A/G polymorphism (OR, 0.75 and 95% CI, 0.58-0.97 for GG+AG vs. AA), but an increased risk for the -318 C/T polymorphism (OR, 2.02 and 95% CI, 1.36-3.00 for TC vs. CC). In summary, the current meta-analysis showed that the +49 A/G and -318 C/T polymorphisms in CTLA-4 constitute risk factors for cervical cancer.

show abstract

CTLA-4, CD28, and ICOS gene polymorphism associations with non-small-cell lung cancer

Cited by 42 publications

References 44 publications

Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies

Association of Five Snps in Cytotoxic T-Lymphocyte Antigen 4 and Cancer Susceptibility: Evidence from 67 Studies

Highlights on immune checkpoint inhibitors in non–small cell lung cancer

Cytotoxic T-lymphocyte-associated antigen-4 polymorphisms and susceptibility to cervical cancer: A meta-analysis

Contact Info

Product

Resources

About